Recent updates in biotech include Novo Nordisk's successful Phase 3 trial of etavopivat for sickle cell disease, Eli Lilly's potential acquisition of Kelonia Therapeutics for over $2 billion, and the promising results of Revolution Medicines' drug daraxonrasib for pancreatic cancer, marking progress in targeting KRAS mutations. Additionally, Helus Pharma's CEO has resigned amid company changes.
Eli Lilly is reportedly nearing a $2 billion acquisition deal for Kelonia Therapeutics, a company developing in-vivo CAR-T therapies that engineer cancer-killing cells within the body. This potential acquisition could signal a strategic move to enhance Eli Lilly's capabilities in cutting-edge cancer treatments, offering a strong investment signal for stakeholders interested in the biotech industry's evolving landscape of targeted therapies.